TARRYTOWN, N.Y, April 5,
2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that it will report its
first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial
markets open. The Company will host a conference call and
simultaneous webcast at 8:30 AM Eastern
Time that day.
Conference Call Information
Participants may access
the conference call live via webcast on the 'Investors and Media'
page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations. To
participate via telephone, please register in advance at this link.
Upon registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. A replay of the
conference call and webcast will be archived on the Company's
website for at least 30 days.
About Regeneron
Regeneron is a leading
biotechnology company that invents, develops and commercializes
life-transforming medicines for people with serious diseases.
Founded and led for nearly 35 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to numerous FDA-approved treatments and
product candidates in development, almost all of which were
homegrown in our laboratories. Our medicines and pipeline are
designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, pain, hematologic conditions, infectious diseases and
rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite®
technologies, such as VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For more information, please visit www.Regeneron.com or follow
@Regeneron on Twitter.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-to-report-first-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2022-301518076.html
SOURCE Regeneron Pharmaceuticals, Inc.